ARA-290 has more clinical trial data than most peptides sold online

ARA-290, sold under research labels and also known as cibinetide, has something almost nothing else on the same product pages has: three completed, randomized, placebo-controlled human trials in an indexed journal, plus a fourth in a related population. That alone separates it from most of the peptide catalog it is marketed alongside. It does not mean the marketing is accurate. The trials that exist test one receptor-selective mechanism in one rare disease, sarcoidosis-associated nerve damage, and a related metabolic trial in type 2 diabetes. They say nothing about general recovery, athletic performance, or the anti-aging framing that shows up in product copy.

What ARA-290 is, and why it doesn’t act like erythropoietin

ARA-290 is a small peptide engineered from the tertiary structure of erythropoietin (EPO), designed to bind the innate repair receptor rather than the classic erythropoietin receptor that drives red blood cell production.^[1]

That distinction is the whole reason this peptide exists. Recombinant EPO already has decades of use for anemia, but using it for its other effect, tissue protection, runs into a hard limit: EPO also raises hematocrit and platelet activation, and that raises thrombosis risk. Researchers wanted the protective signal without the blood-thickening one, so they built a peptide that, on paper, only hits the receptor responsible for the first effect.

The receptor split matters more than the peptide name. EPO’s two effects run through two different receptor arrangements: a homodimer of the EPO receptor (EPOR) drives red cell production, while a heteromer of EPOR and CD131, the beta common receptor, drives tissue protection in other cell types, including immune cells.^[2] That heteromer is what researchers call the innate repair receptor. ARA-290 was built to activate it selectively.

The logic isn’t unique to erythropoietin. Cardio-selective beta blockers replaced older, non-selective ones for the same reason: bias the drug toward the beta-1 receptor in heart tissue and away from beta-2 in the lungs, and you keep the desired signal without the side effect that used to come bundled with it. ARA-290 tries the same trick on a single hormone system, isolating the injury-response signal from the one that thickens blood.

That receptor-engineering story is also why ARA-290 stands apart from most peptides sold under a research label. Compounds like natural peptide blends marketed for recovery usually have no randomized human trial behind them at all, while ARA-290 has four.

The human trials: sarcoidosis-associated small fiber neuropathy

The best-documented human evidence for ARA-290 comes from randomized, placebo-controlled trials in patients with sarcoidosis-associated small fiber neuropathy, including a 64-subject phase 2b trial.^[3]

Sarcoidosis can damage the small nerve fibers responsible for pain and temperature sensation, a complication with no reliably effective treatment. That made it the disease researchers picked to test whether activating the innate repair receptor does anything measurable in humans.

The three sarcoidosis trials

All three tested ARA-290 against placebo in patients with sarcoidosis-associated small fiber neuropathy.

In the first of these, a placebo-controlled pilot trial, ARA-290 treatment was associated with a significantly greater reduction in neuropathic symptom scores than placebo over four weeks.^[4]

-11.5 point drop in neuropathy symptom score with ARA-290, versus -2.9 with placebo PMID 23168581

A separate, later trial using corneal confocal microscopy reported a significant increase in corneal nerve fiber density in patients treated with ARA-290, a structural finding that sits alongside the symptom improvement rather than substituting for it.^[5]

64 subjects in the largest completed ARA-290 trial PMID 28475703

These are interventional randomized trials, the design that supports a causal claim rather than a mere association. An improvement over placebo inside a randomized trial supports causation within that trial’s population and duration. It says nothing about people outside sarcoidosis, and nothing about durations longer than the trial ran.

Mechanism: what’s confirmed and what’s still hypothesized

The receptor-selectivity claim above is well characterized. What happens downstream of it is not, at least not in intact human tissue.

The anti-inflammatory mechanism proposed for the innate repair receptor has been demonstrated largely in animal models and cultured cell lines, for example reduced inflammatory cytokines in cisplatin-exposed human kidney cell lines, rather than confirmed in intact human tissue or organs.^[6]

What that means in practice: the cell-culture and animal work explains why ARA-290 might reduce inflammation and support nerve repair. It does not prove the mechanism plays out the same way in a person’s peripheral nerves over weeks of dosing. The human trials measure outcomes (pain scores, corneal nerve density); they don’t trace the molecular pathway inside a living patient the way the cell-culture work does.

The claim that ARA-290 regenerates small nerve fibers in humans, rather than only reducing pain signaling, has not been established by the published trials. The corneal nerve fiber density increase is suggestive of regeneration, but a rise in a confocal microscopy measurement is not the same thing as confirmed nerve regrowth traced over time in the same patients.

Dosing as published

In a phase 2 trial in patients with type 2 diabetes and neuropathy, ARA-290 was self-administered by daily subcutaneous injection at 4 mg for 28 days.^[7]

That trial is worth a closer look, because it’s the one place ARA-290 was tested outside sarcoidosis. Subjects with type 2 diabetes received ARA-290 or placebo daily for 28 days and were followed for another month off treatment. Neuropathic symptoms, assessed by the PainDetect questionnaire, improved significantly in the ARA-290 group, and corneal nerve fiber density increased in the subset of patients who started below normal.

The published record contains two distinct dosing patterns:

• 2 mg intravenously, three times weekly for 4 weeks (the 2012 sarcoidosis pilot)
• 1, 4 or 8 mg subcutaneously, once daily for 28 days (the phase 2b sarcoidosis trial and the diabetes trial)

Published dosing regimens for ARA-290 exist only for these short clinical trial protocols. There is no published human dosing study for the general recovery or performance uses it’s marketed for online, so any dose sold under those labels is not derived from trial data at all.

Side effects and what’s still unknown

Across the sarcoidosis pilot trial, no safety concerns were raised by clinical or laboratory assessments, with no significant treatment-related adverse events reported.^[4]

What the trials didn’t check: none of the abstracts available for this article report hemoglobin or hematocrit values directly, the specific lab markers that would confirm the peptide truly avoids EPO’s blood-thickening effect in humans. The receptor-selectivity argument is mechanistically sound and supported in cell and animal work, but the human trials as reported leave that specific loop open.

The entire reason ARA-290 was engineered the way it was is to avoid raising hematocrit. Confirming that it doesn’t, with actual lab values from the human trials, would be the most direct evidence for the drug’s core selling point. Until someone publishes those numbers, the selectivity claim rests on receptor biology and animal data rather than a human blood test.

None of the published trials followed patients beyond a treatment window of a few weeks to months, so safety with repeated or extended dosing is unestablished. A 28-day trial with a month of follow-up tells you nothing about what happens after a year of intermittent self-dosing, which is the pattern most people buying this peptide online follow.

Where ARA-290 fits against other engineered EPO derivatives

ARA-290 belongs to a broader class of engineered, nonerythropoietic erythropoietin derivatives, which also includes carbamylated erythropoietin, developed to obtain the tissue-protective benefits of erythropoietin without its erythropoiesis-driven risks.^[8]

Measured against a peptide such as BPC-157, which has no completed placebo-controlled human trial, ARA-290 has a stronger clinical trial record, though one still limited to two indications from a single research program. That distinction is significant: it separates a compound with actual randomized human data from one running entirely on animal work and internet testimony.

It’s also not a large enough record to justify the breadth of what gets claimed for ARA-290 online. Sermorelin sits in a similar spot: real trials exist, but they’re few, small, and don’t cover most of what the compound gets sold for. The pattern across the peptide market, including in GHK-Cu’s evidence base, is the same shape: a legitimate mechanistic story, a handful of real trials in a narrow population, and marketing that runs well past both.

What to watch for

Because the published trials are limited to two research indications from a single lab-affiliated program, whether ARA-290’s benefit generalizes to other neuropathic pain populations remains untested. Diabetic peripheral neuropathy affects far more people than sarcoidosis-associated small fiber loss; a trial testing ARA-290 against that larger population, with hematologic labs reported this time, would tell you far more than another sarcoidosis replication.

Anyone using ARA-290 outside a clinical trial is using a compound whose only safety and efficacy data come from short, company-sponsored studies in specific patient populations. That’s a materially different situation from an FDA-approved drug with post-market surveillance behind it.

Bottom line: ARA-290 is one of the few peptides in this market with real randomized trial data to point to, and that data holds up as far as it goes. It just doesn’t go very far. Two indications, one research group, dosing windows measured in weeks, and a hematocrit question the trials never answered in print.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.